Table 2.

Frequency of non surgical premature menopause by diagnosis, treatment and demographics.

		Non-surgical premature menopause
		Yes		No
		N	%	N	%
Age at diagnosis	0–9	38	2.0	1837	98.0
	10–14	29	5.1	542	94.9
	15–20	43	8.9	442	91.1
Diagnosis	Leukemia	34	3.0	1115	97.0
	Hodgkin Lymphoma	56	16.1	292	83.9
	Kidney Tumors	7	2.0	337	98.0
	Bone Tumors	2	0.6	309	99.4
	Neuroblastoma	3	1.2	251	98.8
	Soft Tissue Sarcomas	4	1.8	220	98.2
	CNS Tumors	1	0.6	156	99.4
	Non Hodgkin Lymphoma	3	2.1	140	97.9
Treatment exposure	Any Alkylating Agents	78	5.7	1283	94.3
	Any Procarbazine	47	23.4	154	76.6
	No procarbazine	63	2.3	2666	97.7
	Procarbazine > 0 – 4000 mg/m2	4	13.8	25	86.2
	Procarbazine ≥ 4000 mg/m2	31	24.2	97	75.8
	No OvRT	16	1.2	1290	98.8
	Minimum OvRT dose > 0–500 cGy	78	5.2	1418	94.8
	Minimum OvRT dose >500 cGy	15	13.0	100	87.0
	Alkylating Agent Only	12	2.2	540	97.8
	OvRT Only	27	3.4	765	96.6
	Alkylating Agent and OvRT	66	8.2	738	91.8
	Procarbazine and OvRT	41	23.8	131	76.2
	Unilateral Oophorectomy	5	8.1	57	91.9
	Stem Cell Transplant	3	17.6	14	82.4
Smoking History	Yes	29	3.7	757	96.3
	No	61	3.5	1680	96.5
	Unknown
Body mass inidex	Above 30	21	3.8	534	96.2
	between 25 and 29.9	26	4.8	516	95.2
	Under 24.9	40	3.6	1077	96.4
	Unknown

OvRT=Ovarian Radiation